REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
13/07/2026
Voltar para busca
Dado oficial do USPTO
KHERION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
13/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42
Data de depósito
04/04/2019
Data de registro
13/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/07/2021
Última transação
13/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
KELLEY, EVELYN
Unidade examinadora
N90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Kherion Technology Limited
Representantes
John P. McCormick Fish & Richardson P.C.
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment and prevention of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disorderscardiovascular diseases or disordersmetabolic diseases or disordersinflammationcancerdiabetes; pharmaceutical preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceuticalmedical and veterinary preparations and substances for the treatment and prevention of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disorderscardiovascular diseases or disordersmetabolic diseases or disordersinflammationcancerdiabetes; pharmaceuticalmedical and veterinary preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases or disorders; enzymes for medical and veterinary purposes; vaccines; diagnostic agentsreagentspreparations and substances for pharmaceuticalmedical and veterinary purposes; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersblood fraction proteins; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases or disordershuman plasma proteins; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersanimal plasma proteins; gene regulatory proteins for medical use; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersantibodies; antibody receptors for medical use; antigens for medical use; antigen receptors for medical use; sanitary preparations for medical and veterinary purposes; preparations for destroying vermin; fungicidesherbicides; molecular components and complexes for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders
Classe 9
Electronic data in recorded form and downloadable electronic publications in the nature of reportsarticlese-books and e-zines relating to enzymesvaccinespharmaceuticals and pharmaceuticalmedical and veterinary preparations and substances
Classe 42
Scientific and technological services and research and design relating thereto relating to enzymesvaccinespharmaceuticals and pharmaceuticalmedical and veterinary preparations and substances; research in the field of molecular biology; pharmaceuticalmedical and veterinary research; industrial analysis in the biologicalpharmaceuticalmedicalveterinary fields; industrial research services in the fields of pharmaceuticalsmedicine and science; researchdevelopmenttesting and evaluation of pharmaceuticals and of pharmaceuticalmedical and veterinary preparations and substances; researchdevelopmenttesting and evaluation of enzymes and of diagnostic agentsreagentspreparations and substances for pharmaceuticalmedical and veterinary purposes; provision of information and consultancy in relation to any of the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/11/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/10/2021
FIMP
FINAL DISPOSITION PROCESSED
23/10/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
13/07/2021
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
03/06/2021
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
27/04/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
17/04/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
17/04/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
13/03/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
24/02/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
24/02/2021
GPNX
NOTIFICATION PROCESSED BY IB
12/12/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
24/11/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/11/2020
PUBO
PUBLISHED FOR OPPOSITION
24/11/2020
GPNX
NOTIFICATION PROCESSED BY IB
21/11/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/11/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/11/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/11/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/10/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
16/10/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/10/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
16/10/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/10/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
27/05/2020
GNFR
FINAL REFUSAL E-MAILED
27/05/2020
CNFR
FINAL REFUSAL WRITTEN
27/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/04/2020
RFNT
REFUSAL PROCESSED BY IB
22/11/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/11/2019
RFRR
REFUSAL PROCESSED BY MPU
02/11/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/10/2019
CNRT
NON-FINAL ACTION WRITTEN
15/10/2019
MAFR
APPLICATION FILING RECEIPT MAILED
05/10/2019
DOCK
ASSIGNED TO EXAMINER
01/10/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
19/09/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KHERION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.